SCHEMBL650790

SCHEMBL650790

CN(C)CCCNc1ncc(C=C2SC(=Nc3ccc4cn[nH]c4c3)NC2=O)s1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.37
MAPT P10636 10/20 0.37
MEN1 O00255 10/20 0.37
LMNA P02545 3/20 0.37
POLB P06746 3/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
PSMD14 O00487 1/20 0.37
ACHE P22303 1/20 0.37
APOBEC3A P31941 1/20 0.36
APOBEC3G Q9HC16 1/20 0.36
RAB9A P51151 4/20 0.36
HCRTR1 O43613 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PTPN7 P35236 1/20 0.35
DUSP3 P51452 1/20 0.35
PTPN12 Q05209 1/20 0.35
PTPN22 Q9Y2R2 1/20 0.35
MAPK1 P28482 3/20 0.35
DYRK3 O43781 1/20 0.35
NPC1 O15118 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10227026 1.00 KMT2A (0.37) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL650789 1.00 KMT2A (0.37) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL651347 0.98 KMT2A (0.37) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL651346 0.98 KMT2A (0.37) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL10227917 0.98 KMT2A (0.37) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL653319 0.95 KMT2A (0.38) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL10226357 0.95 KMT2A (0.38) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL653320 0.95 KMT2A (0.38) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL649534 0.89 ALDH1A1 (0.37) KMT2AMAPTMEN1LMNAPOLB
SCHEMBL10226352 0.89 ALDH1A1 (0.37) KMT2AMAPTMEN1LMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 KMT2A 3437/4885MAPT 3657/4885MEN1 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.